EP3908282
Meðhöndlun á krabbameini sem hefur GNAQ eða GNA11 genastökkbreytingar með prótín-kínasa-C hindrum
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
7.1.2020EP published:
2.7.2025EP application number:
20703606.2
EP translation filed:
17.10.2025Grant published:
15.11.2025EPO information:
European Patent Register
Max expiry date:
6.1.2040Expiry date:
6.1.2027Next due date:
31.1.2027
Title in English:
TREATMENT OF CANCER HAVING GNAQ OR GNA11 GENETIC MUTATIONS WITH PROTEIN KINASE C INHIBITORSLanguage of the patent:
English
Timeline
Today
7.1.2020EP application
2.7.2025EP Publication
17.10.2025Translation submitted
15.11.2025Registration published
6.1.2027Expires
Owner
Name:
Ideaya Biosciences, Inc.Address:
5000 Shoreline Court, Suite 300, South San Francisco, CA 94080, US
Inventor
Name:
KNOX, JohnAddress:
Emerald Hills, CA 94062, US
Name:
LACKNER, MarkAddress:
San Mateo, CA 94403, US
Name:
MOUNIR, ZinebAddress:
Pacifica, CA 94044, US
Name:
O'BRIEN, CarolAddress:
Brisbane, CA 94005, US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
201962789177 PDate:
7.1.2019Country:
US
Classification
Categories:
A61K 31/506, A61K 45/06, A61P 35/00
Annual fees
Number
Paid
Expires
Payer
Number: 7
Paid: 7.1.2026
Expires: 6.1.2027
Payer: Árnason Faktor ehf.